Actualización en el desarrollo de la vacuna contra el dengue

Abstract

Background: Dengue is one of the most viral diseases caused by flavivirus, which can spread rapidly around 125 tropical and subtropical areas in the world. It is estimated that approximately 390 million infections can occur per year. However, immunization does not provide adequate protection against this pathogen, therefore, the development of new vaccines implies an improvement in the health system and society. Nowadays, different clinical trials are in progress, and they will launch a new effective and safe vaccine to counteract the effects that Dengue virus can cause. Objective: Update on the development of the Dengue vaccine. Methodology: A non-experimental study of a descriptive/narrative type will be carried out. Also, a bibliographic review based on articles indexed in various scientific sources, specifically in the PubMed database, limited to the English and Spanish languages from 2018 to 2022. Systematic reviews, meta-analyses, clinical trials and comparative studies will be analyzed. Results: In the new investigations, the clinical and preclinical trials, study the live attenuated vaccines, recombinant subunits, tetravalent DNA and inactivated purified vaccines prevails to develop a new effective vaccine against Dengue. Conclusions: the TV003 or DENVax vaccine is the only one in phase III of clinical trials and the most promising, showing excellent immunity and protection.